At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHVS Pharvaris N.V.
Post-Market Trading 06-07 16:00:49 EDT
15.59
-1.22
-7.26%
盘后15.67
+0.08+0.51%
16:00 EDT
High16.69
Low15.37
Vol16.59K
Open16.60
D1 Closing16.81
Amplitude7.86%
Mkt Cap839.00M
Tradable Cap294.98M
Total Shares53.82M
T/O265.36K
T/O Rate0.09%
Tradable Shares18.92M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Pharvaris (PHVS) and Cue Biopharma (CUE)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.